tbuckley/cabot-search huggingface dataset:
Abstract P4-10-17: Plasma metabolomic signatures associated with long-term breast cancer risk in the SU.VI.MAX prospective cohort
Authors: L Lucie, D Céline, L Bernard, D Aicha, R Adrien, V Marie-Paule, P Mélanie, L Marie, F Tom, C Delphine, Z Laurent, G Pilar, H Serge, D Mélanie, P Valentin, S Bernard, L-M Paule, K-G Emmanuelle, D-P Nathalie, M Claudine, D Stéphanie, P-G Estelle, T Mathilde
Journal: Cancer Research (2019)

Abstract Purpose: Breast cancer is a major cause of death in occidental women. Mechanisms involved in its etiology remain misunderstood. Metabolomics is a powerful tool which may help elucidating novel biological pathways and identify new biomarkers in order to predict breast cancer well before symptoms appear. The aim of this study was to investigate whether untargeted metabolomic signatures from blood draws of healthy women could contribute to better understand and predict the long-term risk of developing breast cancer. Methods: A nested case-control study was conducted within the SU.VI.MAX prospective cohort (13 years of follow-up) to analyze baseline plasma samples of 211 incident breast cancer cases and 211 matched controls by LC-MS mass spectrometry. Multivariable conditional logistic regression models were computed. Results: 83 ions were significantly associated (corrected-pvalue &amp;lt;0.05) with breast cancer risk. Notably, we observed that a lower plasma level of O-succinyl-homoserine and higher plasma levels of valine/norvaline, glutamine/isoglutamine, 5-aminovaleric acid, phenylalanine, tryptophane, γ-glutamyl-threonine, ATBC, 2-amino-cyanobutanoic acid and pregnene-triol sulfate were associated with an increased risk of developing breast cancer during follow-up. Corrected-pvalues ranged from 0.009 (OR=1.43[1.14-1.78] for phenylalanine and OR=1.45[1.15-1.83] for valine/norvaline) to 0.03 (OR=1.28[1.03-1.58] for 2-amino-cyano-butanoic acid). Conclusion: Several pre-diagnostic plasmatic metabolites are strongly associated with long-term breast cancer risk. If confirmed in other independent cohort studies, these results could help to identify healthy women at higher risk of developing breast cancer in the subsequent decade and to propose a better understanding of the complex mechanisms involved in its etiology. Trial registration: SU.VI.MAX, clinicaltrials.gov NCT00272428. Registered 3 January 2006 Keywords: Metabolomics, breast cancer, mass spectrometry, plasma, prospective study Citation Format: Lucie L, Céline D, Bernard L, Aicha D, Adrien R, Marie-Paule V, Mélanie P, Marie L, Tom F, Delphine C, Laurent Z, Pilar G, Serge H, Mélanie D, Valentin P, Bernard S, Paule L-M, Emmanuelle K-G, Nathalie D-P, Claudine M, Stéphanie D, Estelle P-G, Mathilde T. Plasma metabolomic signatures associated with long-term breast cancer risk in the SU.VI.MAX prospective cohort [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-10-17.
Abstract P5-18-09: Performance of Oncotype DX DCIS score across diverse ethnic populations
Authors: P Mittar, S Casella, A Bombonati, O Emiloju, L Jablon, D Schultz, JC Leighton, LJ Solin
Journal: Cancer Research (2019)

Abstract There is a paucity of data on Oncotype DX DCIS Score and ethnic variation. It has been postulated that there are different molecular features /drivers among different ethnic populations. The Oncotype DX DCIS Score is a genomic test designed to analyze the expression of a group of 12 genes which can quantify 10-year local recurrence risk after surgery. The purpose of this study is to evaluate diverse ethnic patients with DCIS relative to traditional clinical pathologic factors and Oncotype DX DCIS Score We analyzed consecutive cases of DCIS from 2011-2017 who underwent Oncotype DX DCIS Score testing at a single institution. Eighty-four female patients were divided into 5 groups based on self-reported ethnicity: White (36%), African American (AA) (48%), Asian (8%), Hispanic (4%) and Other (4%). Clinical and traditional pathologic factors were collected including age, nuclear grade (NG), ER/PR status and Oncotype DX DCIS Score. The distribution of NG and Oncotype DX DCIS Score was analyzed across ethnic groups. The mean age at diagnosis was 63. Overall 99 % of cases were hormone positive. Comparison of White and AA patients revealed a correlation between ethnic group and DCIS Score, with a p value of 0.0087 (Table 1). Similarly, we looked at all five ethnic groups and Oncotype DX DCIS Score and found a p value of 0.022. We evaluated ethnicity with White and AA patients versus NG and obtained a p value of 0.084 (Table 2). In addition, we assessed all five ethnic groups and NG. We obtained a p value of 0.068. No AA patients with DCIS had a high DCIS Score. No patients with low NG DCIS had a high DCIS Score. Analysis of the three factors (NG, ethnicity and DCIS Score) concurrently showed that they are not independent. In summary, our study provides valuable data on Oncotype DX DCIS Score and NG across a diverse patient population. These data highlight the importance of incorporating both traditional clinical pathologic factors and DCIS Score molecular testing for making treatment decision across different ethnic patient populations. Table 1.Comparison of DCIS Score and Ethnic GroupEthnic GroupLow DCIS ScoreIntermediate DCIS ScoreHigh DCIS ScoreAA3730White2704p=0.0087 Table 2.Comparison of Nuclear Grade and Ethnic GroupEthnic GroupNuclear Grade 1Nuclear Grade 2Nuclear Grade 3AA17194White1399p=0.084 Citation Format: Mittar P, Casella S, Bombonati A, Emiloju O, Jablon L, Schultz D, Leighton JC, Solin LJ. Performance of Oncotype DX DCIS score across diverse ethnic populations [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-18-09.
Future doctors: the NHS needs your leadership
Authors: Sarah Curtis
Journal: BMJ (2015)

How you can transform the health service you work for in the future The NHS must transform itself to meet the challenge of continuing to deliver a world class health service in response to an ageing and more complex patient population, and to achieve this within tighter financial limits. Doctors of the future are responsible for the evolution of the NHS to ensure that it survives long term. Junior doctors are already working with policy makers at NHS England to shape a radical reformation of health and social care services. These new services will need engaged, informed doctors with a flair for organisation and teamwork. Future general practitioners could find themselves leading a multidisciplinary community provider team that employs geriatricians, nurses, and social workers. Hospital doctors may set up general practices alongside emergency care within hospitals. Clinical leadership, we are promised, will drive the changes in the NHS. But why is all this happening now? In October 2014, Simon Stevens, the newly appointed chief executive of NHS England, published the NHS Five Year Forward View , which sets out what he sees as the key challenges for the NHS over the next five years.1 Stevens’s team includes clinical fellows at NHS England—junior doctors who are taking time out of training to develop their experience of policy and strategy. The team identified key challenges in three fields: disease prevention, quality of care, and funding and efficiency (see box 1). If these are not dealt with, the report says, the consequences will be a combination of massive spending on avoidable illness, unacceptable variations in care standards, and a limited service. #### Box 1: Three key challenges identified by the NHS Five Year Forward View
Abstract ES6-3: Systems approaches to attacking cancer vulnerabilities defined by metabolic, de-differentiation and genomic instability states
Authors: T Graeber
Journal: Cancer Research (2019)

Abstract Targeted therapies have demonstrated clinically impactful efficacies. Upfront and adaptive tumor heterogeneity and plasticity present a next challenge to advancing cancer therapeutics further. We are using systems biology and integrative omic approaches towards identifying i) vulnerabilities of aggressive tumor types and ii) combination therapies for preventing resistance. We are incorporating functional datasets defining drug sensitivities (drug screens) and genetic vulnerabilities (shRNA knockdown and CRISPR knockout screens) to identify phenotype-associated cellular susceptibilities. In cancer cells highly dependent upon glucose for survival, we found that glucose withdrawal activates a positive feedback loop involving reactive oxygen species (ROS), ROS-mediated inhibition of tyrosine phosphatases, and tyrosine kinase signaling. This loop amplifies ROS to toxic levels, resulting in cell death. In a process that has parallels to the epithelial to mesenchyme transition (EMT), melanoma cells can undergo dedifferentiation. New standard of care therapies, such as kinase inhibition and immunotherapy, can promote dedifferentiation as a therapy escape route. We found that de-differentiated melanomas have increased sensitivity to ferroptosis - a cell death mechanism tied to metabolism and oxidized lipid membranes. Targeting ferroptosis in combination with standard therapies can block this dedifferentiation resistance escape route. Citation Format: Graeber T. Systems approaches to attacking cancer vulnerabilities defined by metabolic, de-differentiation and genomic instability states [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr ES6-3.
Online detection of error-related potentials in multi-class cognitive task-based BCIs
Authors: Rozhin Yousefi, Alborz Rezazadeh Sereshkeh, Tom Chau
Journal: Brain-Computer Interfaces (2019)

One method for improving the accuracy and hence the rate of communication of a brain–computer interface (BCI) is to automatically correct erroneous classifications by exploiting error-related potentials (ErrPs). The merit of such a correction scheme has been demonstrated in both active (e.g. motor imagery) and reactive (e.g. P300) BCIs. Here, we investigated the effect of ErrP-guided error correction in a three-class, active BCI based on cognitive rather than motor imagery tasks using electroencephalography (EEG). Ten able-bodied adults participated in three sessions of data collection. For each participant, a ternary BCI differentiated among idle state and two personally selected cognitive tasks (e.g. mental arithmetic, counting, word generation, and figure rotation). Real-time feedback of the BCI decision was displayed to the participant following each task. EEG data after feedback onset were used to detect ErrPs and correct the BCI's output in the case of detected errors. ErrP-based error correction modestly but significantly improved the average online task classification accuracy (+7%) as well as the information transfer rate (+0.9 bits/min) of the ternary BCI across participants. Our findings support further study of ErrPs in active BCIs based on cognitive tasks.
Abstract P2-08-05: Withdrawn
Authors: D Jaraj, J Ahlgren, L-G Arnesson, Z Einbeigi, J Höijer, M Klintman, P Malmström, E Vikhe Patil, M Sund, I Fredriksson, J Bergh, A Pettersson
Journal: Cancer Research (2019)

Abstract This abstract was withdrawn by the authors. Citation Format: Jaraj D, Ahlgren J, Arnesson L-G, Einbeigi Z, Höijer J, Klintman M, Malmström P, Vikhe Patil E, Sund M, Fredriksson I, Bergh J, Pettersson A. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-05.
You’ve been bleeped: found on the floor
Authors: Andrew Clarke, Sunjay Parmar, Rakesh Patel
Journal: BMJ (2015)

The aim of this series is to present common on-call scenarios that you may face as a junior doctor and to provide a framework to help deal with your reactions when the bleep goes off. By reflecting the voices of a junior doctor and a medical registrar, this series will highlight the different perspectives of both the newly qualified doctor and the more experienced one. We aim to provide you with insights on how best to approach the initial problem and then how to manage the patient once you have reached the ward.

#### Scenario

It is Saturday morning. You are a foundation year 1 (FY1) doctor on call for the general medical wards at a busy district general hospital. You are on a ward round with the on-call medical registrar, reviewing the patients in the high dependency unit when your bleep goes off.

#### Bleep

“Is that the FY1 covering the wards? My name is Tom, staff nurse on ward 4. I’m calling about an 81 year old man called Ed Herts who we have found on the floor. No one saw him fall. He is in a lot of pain over his right side. He was originally admitted with cellulitis, but he has been in hospital for some time now. His observations are stable. Can you please review him?”

### How would you react to this bleep on the phone?

A patient might fall for several reasons. Although this could be a simple slip or trip, patients may also fall due to an underlying medical problem. In the latter case, a fall could alert medical staff to an acute deterioration in the patient’s clinical condition. It is also important to consider that any fall could result in a major complication.[1].

On the phone you need to start to uncover the circumstances surrounding why the patient ended up on the floor. This might be …
You’ve been bleeped: chest pain
Authors: Andrew Clarke, Sunjay Parmar, Rakesh Patel
Journal: BMJ (2014)

The aim of this series is to present common on-call scenarios that you might face as a junior doctor and to provide a framework to help you deal with your reactions when your bleep goes off. By reflecting the voices of a junior doctor and a medical registrar, this series will give the perspectives of both. Our aim is to provide you with insights on how best to approach the initial problem and how to manage the patient once you have reached the ward.

#### Scenario

You are a foundation year 1 doctor (FY1) on call for general medicine at a busy district general hospital. You have just finished all the jobs on your list from your base ward and receive a list of blood results to chase from your colleagues at the daily 1700 handover. You are the only doctor on call and have to cover all nine medical wards in the hospital. Your first bleep is a request to rewrite some drug charts and to prescribe maintenance intravenous fluids for a patient on ward nine, which is in one corner of the hospital. As you arrive on the ward at 1745, your bleep goes off again.

#### Bleep 

“Hi, it’s Gemma, staff nurse on ward two. I’m calling about a patient who has chest pain. He was admitted yesterday from the diabetic foot clinic with an infected foot ulcer. He is a 72 year old man who has a BMI [body mass index] of 42. I was told at handover he has hypertension, angina, gastro-oesophageal reflux, hypothyroidism, and gout. Can you come to review him?”

#### View from the medical registrar

##### How would you react to this bleep?

Chest pain is a symptom with a wide range of differential diagnoses. You will need to review the patient in person to confirm the extent to which you prioritise managing the complaint and gather more information about …
Abstract P3-03-05: Not presented
Authors: S-Y Jung, JH Han, SJ Park, E-G Lee, MH Lee, ES Lee, H-S Kang, KS Lee, IH Park, SH Sim, HJ Jeong, Y Kwon, D-E Lee, J Joo, S-K Kim, S Lee
Journal: Cancer Research (2019)

Abstract This abstract was not presented at the conference. Citation Format: Jung S-Y, Han JH, Park SJ, Lee E-G, Lee MH, Lee ES, Kang H-S, Lee KS, Park IH, Sim SH, Jeong HJ, Kwon Y, Lee D-E, Joo J, Kim S-K, Lee S. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-05.
Nrf2 controls iron homoeostasis in haemochromatosis and thalassaemia via Bmp6 and hepcidin
Authors: Pei Jin Lim, Tiago L. Duarte, João Arezes, Daniel Garcia-Santos, Amel Hamdi, Sant-Rayn Pasricha, Andrew E. Armitage, Hema Mehta, Sarah Wideman, Ana G. Santos, Andreia Santos-Gonçalves, Alireza Morovat, Jim R. Hughes, Elizabeth Soilleux, Chia-Yu Wang, Abraham L. Bayer, Paul Klenerman, Christian B. Willberg, Richard C. Hartley, Michael P. Murphy, Jodie L. Babitt, Prem Ponka, Graça Porto, Hal Drakesmith
Journal: Nature Metabolism (2019)
Abstract P6-13-03: Not presented
Authors: J Glaspy, T Tang, D Rutty, X Yan, I Bondarenko, O Burdaeva
Journal: Cancer Research (2019)

Abstract This abstract was not presented at the conference. Citation Format: Glaspy J, Tang T, Rutty D, Yan X, Bondarenko I, Burdaeva O. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-13-03.
Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
Authors: Martin Filipits, Peter Dubsky, Margaretha Rudas, Richard Greil, Marija Balic, Zsuzsanna Bago-Horvath, Christian F. Singer, Dominik Hlauschek, Krystal Brown, Ryan Bernhisel, Ralf Kronenwett, Johnathan M. Lancaster, Florian Fitzal, Michael Gnant
Journal: Clinical Cancer Research (2019)

Prognostic molecular assays may aid in treatment decisions for women with estrogen receptor (ER)-positive, HER2-negative breast cancer. The prognostic value of a 12-gene expression assay (EndoPredict) was reevaluated in the combined ABCSG-6/8 cohorts with longer clinical follow-up.EndoPredict (EP; molecular score, EPclin score) was evaluated in women with ER-positive, HER2-negative node-positive and node-negative breast cancer who received 5 years of endocrine therapy only (median follow-up, 9.6 years; N = 1,702). Distant recurrence-free rate (DRFR; 95% confidence interval) was assessed 10 and 15 years after diagnosis.Overall, 62.6% of patients had low-risk EPclin scores with significantly improved DRFR relative to high-risk patients (HR, 4.77; 95% CI, 3.37-6.67; P < 0.0001). Ten-year DRFR (0-10 years) was improved among patients with low-risk versus high-risk EPclin scores in the full cohort [95.5% (94.1%-97.0%) vs. 80.3% (76.9%-83.9%)] as well as for patients with node-negative disease [95.5% (94.0%-97.1%) vs. 87.0% (82.6%-91.7%)] or with 1 to 3 positive nodes [95.6% (92.2%-99.1%) vs. 80.9% (75.9%-86.1%)]. The molecular and EPclin scores were significant predictors of DRFR after adjusting for clinical variables, regardless of nodal status. Similar results were observed for late recurrence (5-15 years; HR, 4.52; 95% CI, 2.65-7.72; P < 0.0001). The EPclin score significantly added prognostic information to a late metastasis nomogram (CTS5 score; P < 0.001).This study demonstrates that EPclin can identify patients at low risk for early or late recurrence who may safely forgo adjuvant chemotherapy or extended endocrine therapy, respectively, regardless of nodal status.
Long Noncoding RNA H19 Contributes to Cholangiocyte Proliferation and Cholestatic Liver Fibrosis in Biliary Atresia
Authors: Yongtao Xiao, Runping Liu, Xiaojiaoyang Li, Emily C. Gurley, Phillip B. Hylemon, Ying Lu, Huiping Zhou, Wei Cai
Journal: Hepatology (2019)

Biliary atresia (BA) is a neonatal liver disease featuring cholestasis and severe liver fibrosis (LF). Despite advances in the development of surgical treatment, lacking an early diagnostic marker and intervention of LF invariably leads to death from end-stage liver disease in the early years of life. We previously reported that knockout of sphingosine 1-phosphate receptor 2 (S1PR2) protected mice from bile duct ligation (BDL)-induced cholangiocyte proliferation and LF. Our recent studies further showed that both hepatic and serum exosomal long noncoding RNA H19 (lncRNAH19) levels are correlated with cholestatic injury in multidrug resistance 2 knockout (Mdr2
Abstract P1-08-34: Withdrawn
Authors: Y-J Kang, J Han, E Ko
Journal: Cancer Research (2019)

Abstract This abstract was withdrawn by the authors. Citation Format: Kang Y-J, Han J, Ko E. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-08-34.
The cost of careless talk
Authors: Farzon Nahvi
Journal: BMJ (2012)

My patient, Mr T, was a middle aged man with hepatitis C, cirrhosis, a history of alcoholism and intravenous drug use, and a great sense of humor. He came to me with a bacterial peritonitis and a possible gastrointestinal bleed. He didn’t look too good, and I was happy to learn that he was on the waiting list for a liver transplant. Although the team did our best to control his symptoms in the hospital, a transplant was the only cure.

We got along well and he soon became my favourite patient to visit every morning. He would make requests that only I draw his blood, and I would enjoy running errands for …
Abstract 15851: Increased Inflammation in Pericardial Fluid Persists 48 Hours After Cardiac Surgery
Authors: Brittany Butts, Lee A Goeddel, David J George, Chad Steele, James E Davies, Chih-Chang Wei, Jasmina Varagic, James F George, Carlos M Ferrario, Spencer J Melby, Louis J Dell'Italia
Journal: Circulation (2017)

Introduction: Cardiac surgery causes direct trauma to cardiac tissue and disrupts the normal pericardial fluid (PCF), leaving the heart exposed to PCF and mediastinal contents comprised of inflammatory cells and their products. This can potentially have adverse effects on the myocardium, in particular the thin-walled atria, leading to initiation of postoperative atrial fibrillation (AF). After cardiac surgery, the pericardium remains open, and chest drains are routinely placed to prevent fluid accumulation around the heart. However, few studies have examined inflammation in post-operative PCF composition over an extended period of time. Purpose: The purpose of this study is to describe the trajectory and concentration of pro-inflammatory factors in PCF after cardiac surgery over time and compare levels of inflammatory molecules in post-surgical PCF to those in the blood. Methods: PCF was collected immediately after the pericardial sac was incised with the heart beating (time 0), and from the mediastinal d...
An app to make a surgeon
Authors: John Ferns
Journal: BMJ (2013)

### Available for: Mac and PC, price: £4.99

#### Rating:\***|

Gaining the skills to be a competent surgeon is the ultimate goal for many medical students. But, as opportunities can be limited to practising suturing on banana skins or, if you are lucky, occasionally assisting in theatre by holding skin apart, it is a dream for most students.

And it will likely remain that way for some time; however, there are some innovative approaches being adapted to help us obtain experience in surgical skills.

One such approach is the development of an app called pre<optimise by trainee surgeons in Edinburgh. pre<optimise is not based on a smartphone …
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study
Authors: Celalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, Megan Othus, Zhuoxin Sun, Brittny Major, Mei-Jie Zhang, Elizabeth Storrick, Jacqueline M. Lafky, Selina Chow, Krzysztof Mrózek, Eyal C. Attar, Such Nand, Clara D. Bloomfield, Larry D. Cripe, Martin S. Tallman, Frederick Appelbaum, Richard A. Larson, Guido Marcucci, Gail J. Roboz, Geoffrey L. Uy, Richard M. Stone, Aminah Jatoi, Thomas C. Shea, Marcos de Lima, James M. Foran, Brenda M. Sandmaier, Mark R. Litzow, Harry P. Erba, Arti Hurria, Daniel J. Weisdorf, Andrew S. Artz
Journal: Leukemia (2019)